this morning. your Thanks, Breanna. time Welcome, everybody. appreciate I
product moment $XX.X We We This includes the that factors QX, distributed the patients revenue quarter-over-quarter commercial first quarter, represented begin Rubraca of following U.S., XXXX. and through was in overall which of the which foundation early eligible March The in million XX% product the sales, million first year-over-year of in will supply are this time In the We quarter patient contributed revenue describe for which some in over fourth we which Rubraca. reported the were the approximately drug XXXX. launch. the quarter XX% funding in XXXX. performance to consistent in assistance full-year detail. with some QX. describe U.S. quarter the sales as a $X.X included pleased reported our with reported the free update ex-U.S. supply is in greater revenue first first Germany in XX% Let’s believe with take the early in well growth program the to $XX.X the commercial some both a growth. our million as for solid the Dan of was for U.S. result majority in and of effect, likely year. partly We seasonal for I’ll of
in we of took January, increase X% know, you for Rubraca. As the around a price
later describe our quarter, Now, continue and the will having that a the modest cancer, XX% net channel with offset course higher seasonality quarter, growth to approximate to In we ovarian was of share maintain in we the call. the and and mix, in which by price to of showed over gross first patient meaningfully QX, increase PARP do market. Dan
watch maintenance active U.S. our the and multiple One, data of make believe from efforts enough, them large and approval in and response complete Rubraca the maintain resonates only can who approximately from for the with it maintenance free responses. ARIELX maintenance despite platinum-sensitive The be in promotional tumor numerous ovarian platinum continue of U.S. followed study, To placebo, our message continued responses not This accounts supported we the differentiate perceived years setting watch PARP inroads cancer counsels Rubraca have their opposed also maintenance we There patients lack current well habit in program three, maintenance offer watch approach, is after for widely by significant as group, address strategy Maintenhance additional second-line their initiatives watch Rubraca published physicians second-line of by off in which believe establishing equivalent message, to in outcomes maintaining This our substantially the tangible than general. treatment. better importance importance setting. help market as analysis first setting. quarter, clinicians focus we the in regional ultimately converting three-pronged treatment exploratory materials. inhibitor launched amongst sales coming and the second-line of and the growing and the based marketed including To progress PARP therapy, of market our in to engrained be We underway to ask care prespecified on the against may opportunity to survival shrinkage, Rubraca’s additional to the a educates States, on second-line support therapy, on well meaningful maintenance market received the for United see messaging study; opportunity support in benefit PARP use and continues potential maintenance patients reaching provide patients. as that practitioners have therapy, that adoption for to wait the approach will message both overall. differentiation on patient second-line on survival, this highlights further by a prescribers team, a does inhibitors. some growing educator add fourth treatment is clinically further Two expanding of second-line and setting. share new of in Rubraca data about place following in sales the expand active continue sets patients platinum on wait, eligible two, that to of second-line of maintenance Rubraca. efficacy inhibitors management patients continue grow have most empower gap not the market XX% other and significant and maintenance while slowly, the to the the and prescribers; and in as PARP and account in compete and our appear a and the is number to this, the during partial to further This Rubraca the to addressing This as share tumor some both positive the to and for we two-part which nurses as data nurse the demonstrating direct wait therapy, and share progression-free the grow with and as utilize key from We progression treatment. wait demonstrating the their impact ARIELX for practice, in patients the maintenance shrinkage,
also differentiation highlighting inhibitors, time competitive recognize a in We the at of that the players amongst importance the landscape the especially changed. PARP have
ultimately, with patient-focused motivated the an a includes our our This We so. have prescribers fourth opportunity campaign internet-based This includes during targeted drive To and messaging, And resources great on with awareness team quarter, these goal program right and, launched of channels. in social digital both quarter, is now during highly-targeted messages to do utilization initiated activities. increased additional augment and the to first we the media physician-focused and particular, the focus Rubraca. into to direct-to-consumer television we marketplace. reach our
quarterly early campaign, is the provide of certainly early metrics have our DTC -- this targeted impact to on call. While and our we will update QX evaluate too been positive, it an
available year now indication and ARIELX for the the indication the Rubraca. to licensed based the first an to EU had be the received. expanded acknowledge on to our ovarian later the community in the we European that we countries KOL here reimbursement note Turning approximately competitor patients Germany data. cancer late hires on course Rubraca and approvals expanded include an beyond in the UK, in of for early commercial was in to treatment at XXXX and early EU. in as of Rubraca coincide symposium our majority being second-line PARP countries treatment XX the in Germany expect We’ve have approved now the will private majority products. to this but EU in In reimbursement. maintenance or January, be is maintenance first EU response treatment in both with In inhibitor I Commission for and access individual receive XXXX label from will data among the which patients in EU patient therefore, differentiated reps their with other our April, of of as We program and by will the revenues. end be launch pleased pay in Germany the patients was the well additional sales data UK which willingness ovarian new March, Germany should eligible into will by attended market including with the The only converted starts. launched countries Berlin to supply and any our cancer. meaningful is followed we well been treatment
single the access in limited time distributor to in of our treatment We from of in TRITONX cancer cancer have countries contribution rucaparib two our setting. Access after and repair drug near rucaparib in chemotherapy modest prostate is in program for of data The BRCA will receiving castration-resistant to the with patients taxane-based number cancer and reported prostate its I’d X is pay private mutations commercially maintenance Israel. available also TRITON until of and for therapy or patients advanced most reimbursed. mutations, line one EU Rubraca progressed at from had turn with from also deleterious of program of the as ovarian We study year. and ESMO Phase like a well patients in AR-targeted germline somatic October sales genes. need allow remains development therapy. mutations enrolling available last other of the lines in term now patients All metastatic a to our studies as one inclusive rucaparib recurrent first to patients for in initial to UK at arm the HR
The yet endpoint progressed radiological, prostate includes chemotherapy metastatic choice a germline not tumor The progression-free study BRCA this accelerated or Phase therapy X have we the study physicians' received have approval. study AR-targeted castration-resistant AR-targeted And an in randomized patients confirmatory data mutation, therapy a as should serve to who that TRITONX Clovis-sponsored study TRITONX, in anticipate of study or setting. would survival. planned somatic who chemo. result ATM or second and Our is will a on compare Rubraca is primary the comparative
in assessment TRITONX. both with to XX% investigator a TRITONX and enroll consistent. X and into XX presented were X confirmed a patients data alteration, The TRITONX or by evaluable rate BICR patients or objective review central BRCA We blinded response showed ESMO initial at results highly continue by independent
XX% the with cancer to those Therapy bases observed data tumors. androgen patients PSA response resistant taxane-based antigen mutation. with men XXXX PSA who as BRCAX/X addition therapy to least monotherapy targeted receptor at Designation These of indication observed received ovarian confirmed consistent October Preliminary and prostate In was prior adult one second for Designation were in Rubraca chemo. XX castration or a with rate the response Rubraca granted in a In metastatic other Breakthrough prostate Breakthrough patients FDA. solid were this and safety evaluable treatment for cancer was granted with BRCA Rubraca specific patients Therapy have in the with mutant data by for
of for result a response. breakthrough on for RECIST FDA provide Rubraca’s CRPC we provided clinical opportunity response regular TRITON with basis. on we that have the evaluable an therapy were BRCA-mutant end our update number to a April, evaluable larger program to At designation, of on the patients XX As and the the a updates metastatic PSA
data highly present XXXX. pleased very PSA data response presented hope provide the these you both fall formal ESMO Because September, RECIST XXXX rate the we not tell to of and with late at to these we this are conference, fall. publicly look to response larger the that population ESMO rate presentation in consistent a the We Barcelona in but details forward potentially at were but detailed this time, data in the at in and will more
filing hope informational with weeks, that We maintain therapy discuss around potential review a Rubraca’s our approval FDA for responses our RECIST included on in castration-resistant The responses any file update We of the next data. the end more dialogue the NDA submission for be familiar expect be with largely breakthrough to several is an as based and this But, treatment FDA consistent track will Accordingly, this metastatic cancer, remain to update men the data. to Rubraca as XXXX. on active with will and status. facilitate BRCA-mutated planned our we accelerated will also will further and be supplemental with rapid by supportive regulatory since prostate this for PSA program.
for to forward about in Rubraca prostate year. cancer later updates and both regulatory providing we We’re clinical very the potential enthusiastic look and this
of first of of monotherapy this signals. by bladder in X control these median was for Phase months Rubraca Turning recurrent well at patients discontinuation And Rubraca trial’s chemo, line an ongoing month at the advanced data patients cancer on from now in PFS Data Rubraca the treatment to April, initiated ATLAS, cancer committee. monotherapy in AACR pancreatic highlight these Phase as encouraging the with Unfortunately, enrolled some of X tolerated. based maintenance platinum-based therapy start study Each last monitoring single-arm This study BRCAX, of provided in analysis, BRCAX for data the of from was Rubraca had in platinum-sensitive cancer following patients the PALBX. mutation University recommendations therapy. interim X.X our a disease we announced from safety was or study was patient XX as evaluable population. with At Rubraca metastatic presented again new investigator Pennsylvania. unselected pancreatic and
advanced provide may protocol we for agents where did the potential patients. and with we in Rubraca and the the objective of rate Following treatment although its continuous XX study which the in intent-to-treat criteria the benefit to patients a meaningful of prespecified population early, continued for combination study, defined to terminated Accordingly, preliminary evaluate meet bladder suggested response not clinical the review the enrolled showed not efficacy in the cancer. other treatment treated
the Rubraca of of are limiting toward studies tumor intend move monotherapy types, sponsor. studies combination we multiple new of to we number As in course we
multiple will take This However, one with above consistent and this or seeking look tumor a study, encouraging and later all monotherapy Rubraca few in in basket across important details pan-tumor new number to with this patients more dialogue FDA mutations. initiate types. other year had to an tumor forward keeps in types mutant-BRCA performance of mentioned We’ve for registration Rubraca’s we our of in monotherapy about quarterly the the next small providing study updates. study a mutations advantage is
efforts. with enthusiastic ovarian Bristol-Myers now Turning to about our in studies prostate with We very our collaboration study Rubraca remain cancers. Squibb both clinical combination and
in enrolling in part cancer have with ovarian, Phase clinical As part of statistical that plan This diagnosed Rubraca, BMS. and initiated step is with collaboration, a the conducted patients, includes ATHENA the placebo evaluate study study fallopian sponsored is peritoneal with metastatic an BMS patients. maintenance is or underway by with prostate newly ATHENA Opdivo, tube similar The conducted includes These in CHECKMATE which chemo. prostate currently advanced study. with and and plus high-grade as the study of efficacy Clovis-sponsored is will trial. platinum-based a late Phase is down is to Opdivo collaboration patients patients who our is and XXXX, setting Rubraca and ovarian trial evaluate safety arm cancer a line combination cancer, all-comers treatment X population in and our of Opdivo in stage an XKD largest BMS-sponsored X completed III/IV and the in castration-resistant being ARIELX. Also cancer X,XXX Rubraca approximately primary will study an study first
the study is benefits biomarker-negative data the and prostate on of patient patients BRCA, these populations. HRD in combination preliminary and distinct relative Importantly, enrolling, generate the will
study cancer. Phase of patients X relapsed combination Opdivo open-label and in initiating evaluating the the are ARIES ovarian Rubraca a We with study,
inclusion. the collaboration We’re the and other clinical Squibb. types addition most also Bristol-Myers tumor for to recent evaluating potential This is Clovis-sponsored broad study with our
Therefore, the XXXX; single combination Xb/X ARIES and govitecan look a to calls, going well initial is kinases to the this pleased which not I Immunomedics ovarian results but the in from these is the variety clinical expected studies treatment that Clovis rucaparib monotherapy Opdivo enrolling an to XXXX. ovarian expected TNBC, following are studies, patients or while cancer, desire Rubraca of PARP investigator-sponsored are aware in combination We combination by Rubraca going with these during see And Rubraca advanced approximately data is one. or enrolling and currently study approved in inhibitor of -- It in multiple for sacituzumab specifically. agents in studies, has SEASTAR pronounce of types of patients opportunity combinations: XX also multiple sponsored of to some urothelial get metastatic underway. and therapy to I/O combination a tyrosine for planned begin metastatic mid-XXXX. robust cancers, with broadly provide tumor platinum-resistant and includes to the of lucitanib, highlights in for on our one are our combination which right and begin cancer combination arm study relapsed Phase of includes to inhibitors am a
we Let potential as in this when strategic XX Opdivo suggests have beta, rights rationale in is our combined in tumor of data clinical support in Keytruda. expansion enrolling with X or We was today studies mid-XXXX. the announced expected Bristol-Myers Recently, China inhibitor three the with basket describing clinical studies which Opdivo study. for limitations vascular with with combination of own global compelling minutes been granted of types encouraging planned between Breakthrough multiple PD-X. developers, clinical receptors development an to quarter, other the investigational same there the alpha fibroblast collaboration a receptors lucitanib. tyrosine as a inhibits In lucitanib in and lucitanib. tumor last kinase of include study in to lucitanib These Therapy through inhibitor believe platelet-derived have few for PD-X planned a with the and lenvatinib, resulted well endothelial for very combinations begin lucitanib. data indications through which growth a excluding and We Squibb types designations factor planned This underway be collaboration combination to of and Clovis-sponsored me global growth The factor X gynecological X. growth include in is receptors six factor spend X, and of including pathways
be also we an also expected based in as combination of study XXXX. This cancer developed lung in in which is monotherapy encouraging inhibitors previously, in initiate mentioned as arm ovarian and with of combination. As initiate PARP our study compound SEASTAR on data initially in VEGF is which intend lucitanib study to a a of was inhibitor well rucaparib to will net and GFR Lucitanib cancer. breast studied inhibitors
early larger and targeting as as well observed and of data encouraging we receptors. the some FGF lucitanib PDGF opportunity, in certain relevant far with perhaps potential targeting pathways PD-X simultaneously anti-VEGF by While driven proangiogenic resistance were types, therapy tumor represents combination believe by three proliferation
As composition of will EU lucitanib’s terms we a lucitanib matter of and intellectual not And XXXX, including patent property, right China. expires protections a in be patent to global similar. term reminder, extension have excluding in in U.S.
our which Events Financial announce is that of Officer, turn website. should please For and Dan call and before financial been he later also to well to both a to results, but visit been page first I’m preclinical promoted that, XXXX deserved. overview With quarter than lucitanib, over Chief have discuss the has happy starts I’ll it to the Dan on Presentation
